Barros Mário Henrique M, Zalcberg Ilana R, Hassan Rocio
Bone Marrow Transplantation Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
Pediatr Blood Cancer. 2008 Apr;50(4):765-8. doi: 10.1002/pbc.21331.
A risk group (RG) system to predict bone marrow involvement (BMI) based on clinical and laboratory parameters was previously shown to have prognostic value in adult patients with Hodgkin lymphoma (HL). Our aim was to test the applicability of BMI RG in an independent group of childhood and adolescent HL patients.
Seventy-eight HL patients (range 3-18, median 14 years old) were retrospectively studied, including revision of histopathological diagnosis and bilateral BM biopsies. Patients were divided into BMI high-, standard- and low-RG.
The high-RG included 29.5% of the patients, the standard-RG, 32%, and the low-RG, 38.5%. All the patients in the high-RG had stage III or IV. The five children (6.4%) with BMI were included in the high-RG (P = 0.001, chi(2) test) and had stage IV (P < 0.00001, chi(2) test). The BMI risk group out-performed the clinico-pathologic risk assessment in predicting BMI, showing 100% sensitivity, 75% specificity and a positive predictive value of 0.88. Neither BMI nor risk of BMI was statistically associated to age groups (</=14 years old or >14 years old), suggesting that age is not a risk factor for BMI in the pediatric population.
The application of BMI RG score was able to efficiently foresee BMI in a pediatric group of HL patients, adding independent information to clinico-pathologic BMI risk assessment.
先前已证明,基于临床和实验室参数预测骨髓受累(BMI)的风险组(RG)系统对成人霍奇金淋巴瘤(HL)患者具有预后价值。我们的目的是在一组独立的儿童和青少年HL患者中测试BMI RG的适用性。
对78例HL患者(年龄范围3 - 18岁,中位年龄14岁)进行回顾性研究,包括组织病理学诊断复查和双侧骨髓活检。患者被分为BMI高风险组、标准风险组和低风险组。
高风险组包括29.5%的患者,标准风险组为32%,低风险组为38.5%。高风险组的所有患者均为III期或IV期。五名BMI患者(6.4%)被纳入高风险组(P = 0.001,卡方检验)且均为IV期(P < 0.00001,卡方检验)。BMI风险组在预测BMI方面优于临床病理风险评估,敏感性为100%,特异性为75%,阳性预测值为0.88。BMI及BMI风险与年龄组(≤14岁或>14岁)均无统计学关联,这表明在儿科人群中年龄不是BMI的风险因素。
BMI RG评分的应用能够有效预测儿科HL患者组中的BMI,为临床病理BMI风险评估增加了独立信息。